When will Gossamer Bio report earnings and why does it matter for GOSS stock?

Gossamer Bio reports after market close on Mar 12, 2026. The earnings call matters because management will discuss trial readouts, cash runway, and development plans that can move GOSS stock sharply.

What is Meyka AI's forecast for GOSS stock and implied upside?

Meyka AI's model projects a yearly value of **$1.95**, implying about **250.36%** upside versus the current **USD 0.5553**. Forecasts are model-based projections and not guarantees.

What are the main risks for GOSS stock ahead of earnings?

Key risks include trial-readout ambiguity, the ongoing securities investigation noted on Mar 9, and cash runway concerns. Any negative update can amplify share volatility in GOSS stock.

How does the market value Gossamer Bio relative to peers and its pipeline?

Gossamer has a price-to-sales near **2.96** and EV/Sales **7.36**, which signals a premium on pipeline potential. That premium depends on positive trial data and credible execution for GOSS stock.

US Stocks

GOSS Gossamer Bio NASDAQ $0.56 10 Mar 2026: Pre-market ahead of Mar 12 earnings

ByHuzaifa Zahoor March 10, 2026March 10, 2026

GOSS stock moved sharply in pre-market trade on 10 Mar 2026, rising 10.90% to $0.56 as investors position ahead of Gossamer Bio, Inc.’s NASDAQ-listed earnings announcement due Mar 12. Volume is active, with 9.23M shares trading so far versus a 14.12M average. The company remains a clinical-stage biotech in the Healthcare sector in the United States, and forthcoming trial updates and trial-related litigation are the immediate drivers of the move. We examine near-term catalysts, valuation, technical setup, and the analyst landscape ahead of the call.